These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 29779849)

  • 1. How much progress has there been in the second-line treatment of multiple sclerosis: A 2017 update.
    Maarouf A; Boutière C; Rico A; Audoin B; Pelletier J
    Rev Neurol (Paris); 2018 Jun; 174(6):429-440. PubMed ID: 29779849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
    Wingerchuk DM; Carter JL
    Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on treatments in multiple sclerosis.
    Michel L; Larochelle C; Prat A
    Presse Med; 2015 Apr; 44(4 Pt 2):e137-51. PubMed ID: 25813102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction or escalation therapy for patients with multiple sclerosis?
    Le Page E; Edan G
    Rev Neurol (Paris); 2018 Jun; 174(6):449-457. PubMed ID: 29799415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on disease-modifying therapies for multiple sclerosis.
    Vargas DL; Tyor WR
    J Investig Med; 2017 Jun; 65(5):883-891. PubMed ID: 28130412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Price analysis of multiple sclerosis disease-modifying therapies marketed in the United States.
    Bin Sawad A; Seoane-Vazquez E; Rodriguez-Monguio R; Turkistani F
    Curr Med Res Opin; 2016 Nov; 32(11):1783-1788. PubMed ID: 27359262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?
    Hartung DM; Bourdette DN; Ahmed SM; Whitham RH
    Neurology; 2015 May; 84(21):2185-92. PubMed ID: 25911108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [An update on the treatment options for multiple sclerosis].
    Niino M
    Brain Nerve; 2012 Dec; 64(12):1421-6. PubMed ID: 23209069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should MS be treated by escalation or induction therapy?
    Lazibat I; Nevajda B; Grahovac G; Brinar VV
    Coll Antropol; 2014 Mar; 38(1):385-93. PubMed ID: 24851647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety concerns and risk management of multiple sclerosis therapies.
    Soelberg Sorensen P
    Acta Neurol Scand; 2017 Sep; 136(3):168-186. PubMed ID: 27891572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New and emerging disease modifying therapies for multiple sclerosis.
    Saidha S; Eckstein C; Calabresi PA
    Ann N Y Acad Sci; 2012 Jan; 1247():117-37. PubMed ID: 22224673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States.
    Bonafede MM; Johnson BH; Wenten M; Watson C
    Clin Ther; 2013 Oct; 35(10):1501-12. PubMed ID: 24139422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction therapy for the management of early relapsing forms of multiple sclerosis. A critical opinion.
    D'Amico E; Ziemssen T; Cottone S
    Expert Opin Pharmacother; 2017 Oct; 18(15):1553-1556. PubMed ID: 28826278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging oral therapies for multiple sclerosis.
    Miller CE; Umhauer MA
    J Neurosci Nurs; 2011 Feb; 43(1):3-14; quiz 15-6. PubMed ID: 21338040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of multiple sclerosis during pregnancy - safety considerations.
    Thöne J; Thiel S; Gold R; Hellwig K
    Expert Opin Drug Saf; 2017 May; 16(5):523-534. PubMed ID: 28333552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale for the use of mitoxantrone in multiple sclerosis.
    Edan G; Morrissey S; Le Page E
    J Neurol Sci; 2004 Aug; 223(1):35-9. PubMed ID: 15261558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on reproductive safety of current and emerging disease-modifying therapies for multiple sclerosis.
    Cree BA
    Mult Scler; 2013 Jun; 19(7):835-43. PubMed ID: 23319073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Choosing the best treatment for multiple sclerosis: comparative effectiveness, safety, and other factors involved in disease-modifying therapy choice.
    Happe LE
    Am J Manag Care; 2013 Nov; 19(17 Suppl):s332-42. PubMed ID: 24494634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brazilian Consensus for the Treatment of Multiple Sclerosis: Brazilian Academy of Neurology and Brazilian Committee on Treatment and Research in Multiple Sclerosis.
    Marques VD; Passos GRD; Mendes MF; Callegaro D; Lana-Peixoto MA; Comini-Frota ER; Vasconcelos CCF; Sato DK; Ferreira MLB; Parolin MKF; Damasceno A; Grzesiuk AK; Muniz A; Matta APDC; Oliveira BES; Tauil CB; Maciel DRK; Diniz DS; Corrêa EC; Coronetti F; Jorge FMH; Sato HK; Gonçalves MVM; Sousa NAC; Nascimento OJM; Gama PDD; Domingues R; Simm RF; Thomaz RB; Morales RR; Dias RM; Apóstolos-Pereira SD; Machado SCN; Junqueira TF; Becker J
    Arq Neuropsiquiatr; 2018 Aug; 76(8):539-554. PubMed ID: 30231128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.
    Sørensen PS
    J Neurol Sci; 2011 Dec; 311 Suppl 1():S29-34. PubMed ID: 22206763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.